422 related articles for article (PubMed ID: 26141845)
1. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Zhang Y; Chen Y; Li L; Hölscher C
Behav Brain Res; 2015 Oct; 293():107-13. PubMed ID: 26187689
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease.
Liu W; Li Y; Jalewa J; Saunders-Wood T; Li L; Hölscher C
Eur J Pharmacol; 2015 Oct; 765():284-90. PubMed ID: 26302060
[TBL] [Abstract][Full Text] [Related]
4. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
Zhang L; Zhang L; Li L; Hölscher C
Neuropeptides; 2018 Oct; 71():70-80. PubMed ID: 30017231
[TBL] [Abstract][Full Text] [Related]
6. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
7. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
8. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
9. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
Yang W; Chen YH; Liu H; Qu HD
Int J Mol Med; 2015 Nov; 36(5):1369-76. PubMed ID: 26648012
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
12. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
14. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Bao XQ; Wu LY; Wang XL; Sun H; Zhang D
Naunyn Schmiedebergs Arch Pharmacol; 2015 May; 388(5):549-56. PubMed ID: 25678053
[TBL] [Abstract][Full Text] [Related]
15. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
Zhang L; Zhang L; Li L; Hölscher C
J Parkinsons Dis; 2019; 9(1):157-171. PubMed ID: 30741689
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
18. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Chen Y; Zhang Y; Li L; Hölscher C
Eur J Pharmacol; 2015 Dec; 768():21-7. PubMed ID: 26409043
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
